Connective Tissue Disease Patients With Pulmonary Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-01

Study Completion Date

2030-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adult patients with suspected or confirmed Connective Tissue Disease Patients (CTD)With Pulmonary Hypertension(PH)will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and blood taken. The collection of data and biological material will mirror usual clinical practice as far as possible. Subjects will ideally attend further visits at 3, 6 and 12 months to have bloods taken, outcome measures recorded and questionnaires completed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD

NCT02267200

Hypertension,Pulmonary

COMPLETED

Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes

NCT07082933

Pulmonary Arterial Hypertension (PAH)

NOT_YET_RECRUITING

Serum Bio-markers in Pulmonary Hypertension

NCT04472533

Pulmonary Hypertension, Primary, 4

COMPLETED

The Study Of CT Scans and Echo Parameters in Patients With PAH

NCT00625963

Pulmonary Hypertension

COMPLETED

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072

Secondary Pulmonary Arterial Hypertension

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Connective Tissue Diseases Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Connective Tissue Disease Patients With Pulmonary Hypertension

No Intervention

Intervention Type OTHER

No Intervention

Connective Tissue Disease Patients Without Pulmonary Hypertension

No Intervention

Intervention Type OTHER

No Intervention

healthy

healthy people

No Intervention

Intervention Type OTHER

No Intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Definite diagnosis of CTD included Systemic lupus erythematosus（SLE） diagnosed according to the 2019 The European Alliance of Associations for Rheumatology（EULAR） criteria, primary Sjogren's syndrome (pSS) defined according to the 2016 American College of Rheumatology(ACR) criteria, Systemic Sclerosis(SSc) defined according to the 2013 ACR criteria, mixed connective tissue disease (MCTD) defined by Sharp criteria, and Rheumatoid Arthritis(RA) defined according 2010 ACR criteria of two or more CTD at the same time were defined as having overlap syndrome (OS). Patients who had clinical and serological manifestations suggestive of systemic autoimmune diseases but did not fulfil the classification criteria for CTD were defined as having undifferentiated CTD (UCTD).
* PAH was diagnosed by right heart catheterization was defined as mean Pulmonary Artery Pressure (mPAP)\>20 Millimeters of mercury（mmHg）, Pulmonary Artery Wedge Pressure（PAWP）≤15mmHg, Pulmonary Vascular Resistance（PVR）\>2 Wood

Exclusion Criteria

* significant interstitial lung disease or chronic obstructive pulmonary disease;
* left heart disease or congenital heart disease associated with pulmonary hypertension;
* chronic thromboembolic pulmonary hypertension;
* portal hypertension;
* drug or toxin exposure;
* HIV infection;
* any other diseases known to be associated with PAH;
* age\<18 years.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes